WO2004100864A3 - Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares - Google Patents

Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares Download PDF

Info

Publication number
WO2004100864A3
WO2004100864A3 PCT/MX2004/000031 MX2004000031W WO2004100864A3 WO 2004100864 A3 WO2004100864 A3 WO 2004100864A3 MX 2004000031 W MX2004000031 W MX 2004000031W WO 2004100864 A3 WO2004100864 A3 WO 2004100864A3
Authority
WO
WIPO (PCT)
Prior art keywords
infectious diseases
assists
type
treatment kit
antibiotic therapy
Prior art date
Application number
PCT/MX2004/000031
Other languages
English (en)
French (fr)
Other versions
WO2004100864A2 (es
Inventor
Pando Rogelio Hernandez
Casillas Fernando Lopez
Original Assignee
Univ Mexico Nacional Autonoma
Pando Rogelio Hernandez
Casillas Fernando Lopez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nacional Autonoma, Pando Rogelio Hernandez, Casillas Fernando Lopez filed Critical Univ Mexico Nacional Autonoma
Priority to EP04732521A priority Critical patent/EP1623714A4/en
Priority to JP2006532111A priority patent/JP2007500207A/ja
Priority to CA002525539A priority patent/CA2525539A1/en
Priority to US10/556,376 priority patent/US8840892B2/en
Publication of WO2004100864A2 publication Critical patent/WO2004100864A2/es
Publication of WO2004100864A3 publication Critical patent/WO2004100864A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención describe el uso de inmunomoduladores para apoyar el tratamiento habitual contra enfermedades infecciosas por organismos intracellulares facultativos. Partiendo del análisis de la respuesta inmunológica que se instala en este tipo de infecciones, particularmente la ocasionada por la Tuberculosis, se utiliza un kit de tratamiento que asocia un inmunomodulador del tipo betaglicano soluble, asociado con un agente anti inflamatorio del tipo de bloqueadores de la prostaglandina E que al usarlos conjuntamente modulan la respuesta inmunológica permitiendo que se acorte el tiempo de tratamiento con los antibióticos respectivos.
PCT/MX2004/000031 2003-05-13 2004-05-12 Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares WO2004100864A2 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04732521A EP1623714A4 (en) 2003-05-13 2004-05-12 TREATMENT KIT USED IN CONJUNCTION WITH ANTIBIO THERAPY FOR THE TREATMENT OF INTRACELLULAR INFECTIOUS DISEASES
JP2006532111A JP2007500207A (ja) 2003-05-13 2004-05-12 細胞内感染性疾患の抗生物質治療を助ける治療用キット
CA002525539A CA2525539A1 (en) 2003-05-13 2004-05-12 Treatment kit to assist in antibiotic therapy in intracellular infectious diseases
US10/556,376 US8840892B2 (en) 2003-05-13 2004-05-12 Method of administering antibiotic therapy for treating intracellular infectious diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXPA03004172A MXPA03004172A (es) 2003-05-13 2003-05-13 Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares.
MXPA/A/2003/004172 2003-05-13

Publications (2)

Publication Number Publication Date
WO2004100864A2 WO2004100864A2 (es) 2004-11-25
WO2004100864A3 true WO2004100864A3 (es) 2005-12-15

Family

ID=33448397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2004/000031 WO2004100864A2 (es) 2003-05-13 2004-05-12 Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares

Country Status (5)

Country Link
US (1) US8840892B2 (es)
EP (1) EP1623714A4 (es)
JP (1) JP2007500207A (es)
MX (1) MXPA03004172A (es)
WO (1) WO2004100864A2 (es)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010610A1 (en) * 1993-10-15 1995-04-20 La Jolla Cancer Research Foundation BETAGLYCAN POLYPEPTIDES HAVING TGF-β BINDING ACTIVITY
WO1998010056A1 (en) * 1996-09-03 1998-03-12 Health Research Inc. Treatment of antigen presenting cells to modulate antigen presenting cell function
US20010049360A1 (en) * 1999-12-15 2001-12-06 Wylie Vale Betaglycan as an inhibin receptor and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010215A1 (en) * 1991-11-15 1993-05-27 Memorial Sloan-Kettering Cancer Center Purified proteoglycan betaglycan, compositions, and methods
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010610A1 (en) * 1993-10-15 1995-04-20 La Jolla Cancer Research Foundation BETAGLYCAN POLYPEPTIDES HAVING TGF-β BINDING ACTIVITY
WO1998010056A1 (en) * 1996-09-03 1998-03-12 Health Research Inc. Treatment of antigen presenting cells to modulate antigen presenting cell function
US20010049360A1 (en) * 1999-12-15 2001-12-06 Wylie Vale Betaglycan as an inhibin receptor and uses thereof

Also Published As

Publication number Publication date
EP1623714A2 (en) 2006-02-08
WO2004100864A2 (es) 2004-11-25
MXPA03004172A (es) 2004-11-18
JP2007500207A (ja) 2007-01-11
EP1623714A4 (en) 2009-07-22
US8840892B2 (en) 2014-09-23
US20060251657A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
WO2003075857A3 (en) Amino-methyl substituted tetracycline compounds
EP1791958A4 (en) YEAST / BACTERIA-TWO-HYBRID SYSTEM AND METHOD OF APPLICATION THEREOF
EA200600620A1 (ru) Набор для ингаляции с ингаляционным порошком, содержащим тиотропий
WO2005060707A3 (en) Methods of use of probiotic lactobacilli for companion animals
WO2005060709A3 (en) Methods of use of probiotic bifidobacteria for companion animals
UA94221C2 (en) Lipocalin protein
MY137757A (en) Therapeutic treatment
WO2002069945A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
EP2698167A3 (en) Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
WO2005102392A3 (en) Combinations for treating hiv infection
WO2007070613A3 (en) Rifamycin analogs and uses thereof
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
EP1663959A4 (en) NEW AMIDINE COMPOUNDS FOR THE TREATMENT OF MICROBIAL INFECTIONS
ZA202105285B (en) Antibody against human il-4ra and use thereof
WO2006040574A3 (en) Lipocalin protein
WO2004066967A3 (en) Method and kit for reducing the symptoms of peripheral vascular disease
MX2007002277A (es) Metodos para formar retinoides y usos de los mismos.
HK1106253A1 (en) Desoxo-nonadepsipeptides
WO2004094373A3 (en) A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2003094367A3 (en) Improved first aid kit instructions
EP1566448A3 (de) Differenzialdiagnostik mit Hepcidin
WO2004100864A3 (es) Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares
WO2007071986A8 (en) Use of whole bacterial cells (actinomycetales) for maternal administration to modulate offspring immune response
EP4121433A4 (en) BORIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006532111

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10556376

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2525539

Country of ref document: CA

Ref document number: 2004732521

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004732521

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 10556376

Country of ref document: US